Log in to search using one of your social media accounts:

 

Africa:Is SA 'Among the Top Six in the World' for Nuclear Medicine Ingredients?
[Africa Check] South Africa's third energy minister for 2017 has high praise for the country's nuclear capabilities. Here's what we know about South Africa's contribution to nuclear medicine. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 15, 2017 Category: African Health Source Type: news

A Radioactive Cloud from Russia Swept Over Europe — and No One Knows Why
A mysterious radioactive cloud that swept through much of Europe this fall has officials baffled. The cloud was harmless and has dissipated, France’s Institute for Radiological Protection and Nuclear Safety wrote in a statement Thursday, but between Sept. 27 and Oct. 13, the radioactive nuclide Ruthenium 106 was detected in “the majority of European countries.” Experts aren’t totally sure where the substance came from, though testing suggests it was first released during the last week of September in Russia or Kazakhstan, likely somewhere between Russia’s Volga River and Ural Mountains. &ldquo...
Source: TIME.com: Top Science and Health Stories - November 10, 2017 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized europe France Nuclear onetime radiaoctive Science Source Type: news

Novel nuclear medicine test can identify kidney transplant infection
(Society of Nuclear Medicine and Molecular Imaging) German scientists have developed a novel nuclear medicine test that can determine whether a kidney transplant patient has developed infection in the transplanted tissue. The study, which utilizes positron emission tomography/magnetic resonance imaging (PET/MRI), is presented in the December issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 8, 2017 Category: International Medicine & Public Health Source Type: news

Q & amp;A: How to Prepare for an AI-Driven Future
For years the role of robotics and artificial intelligence within the realm of medtech has been hyped as the future of innovation and device development. Now that technological advances are beginning to catch up to our imagination, how will advanced robotic and AI technologies begin to reshape the medtech landscape?  Srihari Yamanoor With advances in machine learning and robotic design, artificial intelligence is poised to have a dramatic impact on the medical device field. With innovative opportunities on both the diagnostic and therapeutic sides of medicine, AI technologies could be the key that unlocks...
Source: MDDI - November 7, 2017 Category: Medical Devices Authors: Kristopher Sturgis Tags: BIOMEDevice San Jose Assembly and Automation Digital Health Source Type: news

FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness
(Society of Nuclear Medicine and Molecular Imaging) Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC). In a study presented in the featured clinical investigation article of the November issue of The Journal of Nuclear Medicine, they used 18F-fluorodeoxyglucose (FDG) PET/CT imaging to show that the amount of cell-free tumor DNA circulating in the bloodstream correlates with tumor metabolism (linked to cancer aggressiveness), not tumor burden (amount of cancer in the body). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 6, 2017 Category: International Medicine & Public Health Source Type: news

Persistent cramps are a symptom of colorectal cancer – but is a CURE on horizon? 
COLORECTAL cancer patients could soon benefit from a new, 100 per cent effective, nuclear medicine treatment, that doesn ’t have any side effects. (Source: Daily Express - Health)
Source: Daily Express - Health - November 3, 2017 Category: Consumer Health News Source Type: news

New system for treating colorectal cancer can lead to complete cure
In this study with a mouse model, researchers achieved a 100-percent cure rate -- without any treatment-related toxic effects. The study is reported in the November featured article in The Journal of Nuclear Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 2, 2017 Category: International Medicine & Public Health Source Type: news

Novartis to buy French nuclear medicine group AAA
Drugmaker to pay $3.9bn for company that specialises in radio pharmaceuticals (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 30, 2017 Category: Pharmaceuticals Source Type: news

SNMMI sets AUC guidelines for malignant disease
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published...Read more on AuntMinnie.comRelated Reading: SNMMI, IAEA collaborate on training ASNC, SNMMI advise on cardiac sarcoidosis SNMMI posts use criteria for hepatobiliary scintigraphy SNMMI taps new slate of officers for 2017-2018 SNMMI partners with NDSC on appropriate use criteria (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 25, 2017 Category: Radiology Source Type: news

SNMMI, IAEA collaborate on training
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International...Read more on AuntMinnie.comRelated Reading: ASNC, SNMMI advise on cardiac sarcoidosis SNMMI posts use criteria for hepatobiliary scintigraphy SNMMI taps new slate of officers for 2017-2018 ESR, IAEA partner to advance imaging IAEA debuts radiotherapy patient safety tool IAEA creates database to record R/F incidents (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 24, 2017 Category: Radiology Source Type: news

SNMMI publishes appropriate use criteria for FDG PET/CT imaging of cancer patients
(Society of Nuclear Medicine and Molecular Imaging) The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. As cancer patients move through therapy, FDG PET/CT has proven an effective tool for assessing treatment response and updating the stage of malignancy. This AUC aims to improve utilization and guide providers across specialties in its use. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2017 Category: International Medicine & Public Health Source Type: news

Biodex Unveils Next Generation Atomlab 500 Dose Calibrator & Wipe...
Leader in nuclear medicine and molecular imaging solutions releases their latest Atomlab line with a sleek new design, enhanced user experience, and improved connectivity for the modern technologist...(PRWeb October 14, 2017)Read the full story at http://www.prweb.com/releases/2017/10/prweb14799264.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 14, 2017 Category: Pharmaceuticals Source Type: news

JNM articles focus on NM training requirements
Should prospective nuclear medicine (NM) clinicians learn in partnership with...Read more on AuntMinnie.comRelated Reading: SNMMI partners with NDSC on appropriate use criteria SNMMI rejects plan to dissolve ABNM SNMMI opposes proposed changes in tech duties Nuclear medicine residents see 'dismal' job market Combo residency could address nuclear medicine job woes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 5, 2017 Category: Radiology Source Type: news

Novel PET tracer identifies most bacterial infections
(Society of Nuclear Medicine and Molecular Imaging) Stanford University medical scientists have developed a novel imaging agent that could be used to identify most bacterial infections. The study is the featured basic science article in The Journal of Nuclear Medicine's October issue. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 5, 2017 Category: International Medicine & Public Health Source Type: news

New targeted alpha therapy protocol for advanced prostate cancer
(Society of Nuclear Medicine and Molecular Imaging) Therapy options are limited for men with advanced-stage, metastatic castration-resistant prostate cancer, but a new treatment protocol offers hope. In the featured article of The Journal of Nuclear Medicine's October issue, German researchers report on their novel dosing regimen for actinium-225-labeled targeted alpha therapy of patients with prostate specific membrane antigen (PSMA)-positive tumors. The protocol balances treatment response with toxicity concerns to provide the most effective therapy with the least side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 3, 2017 Category: Cancer & Oncology Source Type: news

What Clinical Signs Can Be Associated With Benign External Hydrocephalus?
Discussion Hydrocephalus is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles and/or subarachnoid spaces. External hydrocephalus is a communicating hydrocephalus often defined as the patient having a rapidly enlarging head circumference (HC) and enlargement of the subarachnoid spaces especially over the frontal lobes with normal or moderately enlarged ventricles. Benign external hydrocephalus (BEH) is a self-limited external hydrocephalus that occurs during infancy and resolves spontaneously in childhood, usually by age 2 years, that is felt to not cause significant problems. It was first described by...
Source: PediatricEducation.org - October 2, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Mirada's deep-learning contours match human-drawn contours
Imaging software developer Mirada Medical revealed during the American Society...Read more on AuntMinnie.comRelated Reading: Mirada showcases XD:PACS at RSNA 2016 Philips, Mirada sign distribution deal Mirada launches nuclear medicine software at RSNA 2015 Former Philips CEO joins Mirada Medical Mirada, BTG develop new dosimetry software (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 25, 2017 Category: Radiology Source Type: news

Theranostics: Paintball targeting of cancer cells combined with precision therapy
(Society of Nuclear Medicine) The Journal of Nuclear Medicine's September supplement shines a spotlight on theranostics and its increasingly important role in delivering precision medicine. Theranostics refers to the combination of a predictive biomarker, identified through diagnostic imaging using radiolabeled ligands (which lock onto the specific cancer cell receptor/biomarker), with precise therapy targeted on the now-marked cancer cells. The cancer cells are destroyed, while healthy cells are unharmed -- minimizing side effects and improving quality of life for patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 13, 2017 Category: Cancer & Oncology Source Type: news

Double targeting ligands to identify and treat prostate cancer
(Society of Nuclear Medicine) Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects. The study is presented in the featured basic article of the September issue of the Journal of Nuclear Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 7, 2017 Category: Cancer & Oncology Source Type: news

New technique gives a clearer image of immunotherapy results in advanced brain cancer
FINDINGSResearchers led by Robert Prins, a member of the UCLA Jonsson Comprehensive Cancer Center, have developed a new approach for brain imaging that can better distinguish immune responses from tumor growth in both preclinical studies and in people with glioblastoma.BACKGROUNDDespite clinical advances in immunotherapy for cancer, non-invasive monitoring of tumor growth (especially in people with brain tumors) has been a significant problem. When clinicians use traditional medical imaging processes, the inflammation that sometimes results from immunotherapies can resemble neurological decline and tumor growth.METHODPrins...
Source: UCLA Newsroom: Health Sciences - September 5, 2017 Category: Universities & Medical Training Source Type: news

FDG-PET/CT predicts melanoma patients' response to immune checkpoint inhibitor therapy
(Society of Nuclear Medicine) Research highlighted in the featured article of the September issue of The Journal of Nuclear Medicine demonstrates that combined PET/CT scanning early in treatment of advanced melanoma could identify whether the therapy will benefit a particular patient. As the therapy has potentially serious side-effects, early determination of ineffectiveness could avert unnecessary risk exposure and provide the option of a different treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 5, 2017 Category: Cancer & Oncology Source Type: news

SNMMI 2017-2019 Wagner-Torizuka Fellowship recipients announced
(Society of Nuclear Medicine) The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce the recipients of the 2017-2019 SNMMI Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 by the late Henry N. Wagner, Jr., MD, and the late Kanji Torizuka, MD, PhD, is designed to provide extensive training and experience in the fields of nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 24, 2017 Category: International Medicine & Public Health Source Type: news

First human application of novel PET tracer for prostate cancer
(Society of Nuclear Medicine) In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 7, 2017 Category: Cancer & Oncology Source Type: news

SNMMI posts use criteria for hepatobiliary scintigraphy
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published...Read more on AuntMinnie.comRelated Reading: SNMMI Image of the Year awarded to German researchers SNMMI taps new slate of officers for 2017-2018 SNMMI partners with NDSC on appropriate use criteria SNMMI offers appropriate use criteria for 2 cancers SNMMI gets nod from CMS for appropriate use criteria (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 4, 2017 Category: Radiology Source Type: news

SNMMI publishes appropriate use criteria for hepatobiliary scintigraphy in abdominal pain
(Society of Nuclear Medicine) The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for hepatobiliary scintigraphy in abdominal pain. This is the third in a series of new AUC developed by SNMMI in its role as a qualified provider-led entity (PLE) under the Medicare Appropriate Use Criteria Program for Advanced Diagnostic Imaging. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 3, 2017 Category: International Medicine & Public Health Source Type: news

SNMMI honors outstanding contributors at 2017 annual meeting
(Society of Nuclear Medicine) The Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization, recognized contributions to the field of nuclear medicine and molecular imaging during its 2017 Annual Meeting in Denver, Colorado. Several awards ceremonies were held to recognize the valuable role SNMMI members play in advancing the diagnosis and treatment of heart disease, cancer and neurological conditions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 2, 2017 Category: International Medicine & Public Health Source Type: news

New imaging tracer allows early assessment of abdominal aortic aneurysm risk
(Society of Nuclear Medicine) Yale University researchers have developed a way in which medical imaging with SPECT/CT could potentially be used to assess a patient's rupture risk for abdominal aortic aneurysm. Delaying surgical treatment can be life-threatening, and this new type of imaging could allow physicians to diagnose disease and better plan its management. The study is presented in the featured article of the August issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2017 Category: International Medicine & Public Health Source Type: news

Europe Backs Nuclear Medicine for Cancer That Killed Steve Jobs Europe Backs Nuclear Medicine for Cancer That Killed Steve Jobs
A nuclear medicine targeting gastroenteropancreatic neuroendocrine tumours (NETs) won a green light from EU regulators on Friday, boosting prospects for its developer Advanced Accelerator Applications.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - July 24, 2017 Category: Radiology Tags: Radiology News Source Type: news

Europe backs nuclear medicine for cancer that killed Steve Jobs
LONDON (Reuters) - A nuclear medicine targeting the type of cancer that killed Steve Jobs won a green light from EU regulators on Friday, boosting prospects for its developer Advanced Accelerator Applications. (Source: Reuters: Health)
Source: Reuters: Health - July 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

SNMMI technologist section announces 2017 award winners
(Society of Nuclear Medicine) The Society of Nuclear Medicine and Molecular Imaging's Technologist Section (SNMMI-TS) -- an international scientific and medical organization --r ecognized contributions to and work in the field of nuclear medicine and molecular imaging during the SNMMI 2017 Annual Meeting in Denver, Colorado, held June 10-14. Several awards ceremonies were held to recognize the valuable role that SNMMI-TS members play in advancing the discipline of nuclear medicine technology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 20, 2017 Category: Cancer & Oncology Source Type: news

Phase II Ssudy: Radiotherapy dose increase to hypoxic NSCLC lesions
(Society of Nuclear Medicine) Fluorine-18-fluoromisonidazole (FMISO) is a PET radiotracer that is widely used to diagnose hypoxia (insufficient oxygen supply to tissue), and non-small cell lung cancer (NSCLC) patients with FMISO uptake are known to face a poor prognosis. A multicenter French Phase II study featured in the July issue of The Journal of Nuclear Medicine investigated whether a selective radiotherapy dose increase to tumor areas with significant FMISO uptake in NSCLC patients could improve outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 10, 2017 Category: Cancer & Oncology Source Type: news

Phase II Study: Radiotherapy dose increase to hypoxic NSCLC lesions
(Society of Nuclear Medicine) Fluorine-18-fluoromisonidazole (FMISO) is a PET radiotracer that is widely used to diagnose hypoxia (insufficient oxygen supply to tissue), and non-small cell lung cancer (NSCLC) patients with FMISO uptake are known to face a poor prognosis. A multicenter French Phase II study featured in the July issue of The Journal of Nuclear Medicine investigated whether a selective radiotherapy dose increase to tumor areas with significant FMISO uptake in NSCLC patients could improve outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 10, 2017 Category: Cancer & Oncology Source Type: news

Novel PET tracer detects small blood clots
(Society of Nuclear Medicine) Blood clots in veins and arteries can lead to heart attack, stroke, and pulmonary embolism, which are major causes of mortality. In the featured article of The Journal of Nuclear Medicine's July 2017 issue, German researchers show that targeting GPIIb/IIIa receptors, the key receptor involved in platelet clumping, with a fluorine-18 labeled ligand is a promising approach for diagnostic imaging. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 6, 2017 Category: International Medicine & Public Health Source Type: news

The Journal of Nuclear Medicine impact factor increases
(Society of Nuclear Medicine) The Journal of Nuclear Medicine (JNM) -- the flagship publication of the Society of Nuclear Medicine and Molecular Imaging -- is again ranked among the top medical imaging journals worldwide, according to the 2016 Journal Citation Reports © published by Thomson Reuters. JNM's impact factor went up from 5.849 to 6.646. Among nuclear medicine journals, JNM has the highest number of citations and citable articles, the highest average five-year impact factor, and the highest influence score. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 20, 2017 Category: International Medicine & Public Health Source Type: news

SNMMI: Education eases patients' nuclear medicine fears
DENVER - By providing basic educational materials on nuclear medicine and the...Read more on AuntMinnie.comRelated Reading: JNM article questions radiation dangers for kids Education enlightens patients to radiologist's role Are radiation dose guidelines scaring patients? Most hospitals follow pediatric nuclear medicine dose guidelines Does low-level radiation really cause cancer? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 15, 2017 Category: Radiology Source Type: news

SNMMI Image of the Year awarded to German researchers
DENVER - The Society of Nuclear Medicine and Molecular Imaging (SNMMI) on Wednesday...Read more on AuntMinnie.comRelated Reading: Novel PET combination awarded SNMMI Image of the Year SNMMI: PET prostate image lands Image of the Year honors SNMMI: Alzheimer's PET tracer wins Image of the Year award Radium-223 dichloride is focus of SNMMI Image of the Year SNM Image of the Year goes to Bi-123 DOTATOC radiotracer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 14, 2017 Category: Radiology Source Type: news

SNMMI Image of the Year: PET and optical imaging for prostate cancer diagnosis and therapy
(Society of Nuclear Medicine) The winning image, presented by German researchers at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), clearly demonstrates how combining the advantages of 68Ga-PSMA PET and intraoperative gamma and fluorescence imaging results in better tumor identification before and during surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2017 Category: Cancer & Oncology Source Type: news

Dual-agent PET/MR with time of flight detects more cancer
(Society of Nuclear Medicine) Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (18F-NaF) followed by quantitative scanning significantly improves image quality and detection of bone metastases at a lower dose, according to research presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2017 Category: Cancer & Oncology Source Type: news

Prostate PET/CT targets more cancer and improves patient care
(Society of Nuclear Medicine) A new study that includes data from four Australian medical centers shows that Ga-68 Prostate Specific Membrane Antigen (PSMA) PET/CT detects prostate cancer not caught by more conventional imaging, thus affecting treatment plans. The research was presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2017 Category: Cancer & Oncology Source Type: news

Targeted radionuclide treatment for neuroendocrine tumours improves quality of life
A study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging reports that a novel peptide receptor radionuclide therapy significantly improves wellbeing for patients with malignant neuroendocrine tumours.Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 13, 2017 Category: Endocrinology Source Type: news

Immuno-PET shows promise for detecting and treating pancreatic tumors
(Society of Nuclear Medicine) A first-in-human study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates the feasibility and safety of the novel human monoclonal antibody HuMab-5B1 with highly specific targeting for the cancer antigen (CA) 19-9, which is expressed on pancreatic tumors and a variety of other malignancies, including small cell lung cancer and tumors of the gastrointestinal system. It holds the promise of better identifying tumors and directing treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 13, 2017 Category: Cancer & Oncology Source Type: news

Single dual time-point PET scan identifies dual Alzheimer's biomarkers
(Society of Nuclear Medicine) Identifying Alzheimer's disease before major symptoms arise is critical to preserving brain function and helping patients maintain quality of life. A new study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates that a single dual time-point PET scan could identify important biomarkers of the disease. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 13, 2017 Category: International Medicine & Public Health Source Type: news

Combining radionuclide therapy with a PARP inhibitor slows neuroendocrine tumor growth
(Society of Nuclear Medicine) Patients with neuroendocrine tumors (NETs) may experience fewer symptoms and survive longer by undergoing peptide-receptor radionuclide therapy (PRRT) combined with a drug that makes tumor cells more sensitive to radiation therapy, say researchers presenting at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2017 Category: International Medicine & Public Health Source Type: news

Personalized PRRT improves radiation delivery to neuroendocrine tumors
(Society of Nuclear Medicine) Neuroendocrine cancer is exceedingly difficult to manage and unlikely to be cured, but researchers intend to slow progression of these tumors and aid survival by personalizing patient dose of peptide-receptor radionuclide therapy (PRRT), according to research presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2017 Category: International Medicine & Public Health Source Type: news

At annual meeting, SNMMI recognizes new fellows for distinguished service
(Society of Nuclear Medicine) The Society of Nuclear Medicine and Molecular Imaging (SNMMI) recognized seven new SNMMI Fellows during a Special Plenary Session at the society's 2017Annual Meeting, held June 10-14 in Denver, Colorado. The SNMMI Fellowship was established last year to recognize distinguished service to the society as well as exceptional achievement in the field of nuclear medicine and molecular imaging. It is one of the most prestigious formal recognitions available to long-time SNMMI members. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2017 Category: International Medicine & Public Health Source Type: news

Targeted radionuclide treatment for neuroendocrine tumors improves quality of life
(Society of Nuclear Medicine) Malignant neuroendocrine tumors, commonly called NETs, are easy to miss and associated with discouraging survival rates and poor quality of life. A study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a novel peptide receptor radionuclide therapy (PRRT) is significantly improving patient wellbeing. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 12, 2017 Category: Cancer & Oncology Source Type: news

Martin G. Pomper, MD, PhD, receives SNMMI Paul C. Aebersold Award in nuclear medicine
(Society of Nuclear Medicine) Martin G. Pomper, MD, PhD, director of nuclear medicine and molecular imaging and professor in the Russell H. Morgan Department of Radiology and Radiological Science at The Johns Hopkins University School of Medicine in Baltimore, Maryland, has been named the 2017 recipient of the prestigious Paul C. Aebersold Award. Pomper was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its annual meeting, held June 10-14 in Denver, Colorado. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 11, 2017 Category: Cancer & Oncology Source Type: news

Targeted photodynamic therapy shown highly effective against prostate cancer
(Society of Nuclear Medicine) Researchers presenting a preclinical study at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated the efficacy and optimal dose for targeted photodynamic therapy (tPDT) to treat prostate cancer before and during surgery. Prostate-specific membrane antigen (PSMA) was targeted with an anti-PSMA antibody radiolabeled with the tracer indium-111 (111In) and coupled with specialized photosensitizers that cause cell destruction upon exposure to near-infrared (NIR). The combined formula is 111In-DTPA-D2B-IRDye700DX. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 11, 2017 Category: Cancer & Oncology Source Type: news

ec2 to acquire software firm Numa
In a move that will unite developers of nuclear medicine software, ec2 Software...Read more on AuntMinnie.comRelated Reading: Numa debuts dose reporting software at RSNA 2016 BioDose and NMIS rebrand as ec2 Software Numa adopts virtual model for software Numa announces molecular agreement with Siemens Numa to debut workflow package at SNM show (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 9, 2017 Category: Radiology Source Type: news

JNM article questions radiation dangers for kids
A group of researchers are taking issue with the widely held theory that even...Read more on AuntMinnie.comRelated Reading: Are radiation dose guidelines scaring patients? Most hospitals follow pediatric nuclear medicine dose guidelines Article blasts LNT theory of radiation harm U.S. NRC starts review of LNT radiation theory Does low-level radiation really cause cancer? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 8, 2017 Category: Radiology Source Type: news